SCHEMBL4429576

SCHEMBL4429576

Cc1nccn1CCC(=O)N1CCN(c2cccc(Cl)c2)CC1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 6/20 0.64
HTR7 P34969 5/20 0.64
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 5/20 0.59
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 1/20 0.57
TSHR P16473 1/20 0.57
MAPT P10636 3/20 0.55
HSD17B10 Q99714 1/20 0.54
F10 P00742 1/20 0.53
LMNA P02545 1/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422476 0.88 HTR7 (0.60) HTR1AHTR7MEN1KMT2ASMN1; SMN2
SCHEMBL4423543 0.86 HTR1A (0.63) HTR1AHTR7MEN1KMT2ASMN1; SMN2
SCHEMBL4426703 0.84 LMNA (0.57) HTR1AHTR7KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4417108 0.79 ALDH1A1 (0.59) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL4422252 0.79 MAPT (0.57) MEN1KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL4422360 0.78 HTR1A (0.64) HTR1AHTR7MEN1KMT2ASMN1; SMN2
SCHEMBL4419765 0.78 F10 (0.57) HTR1AHTR7MEN1KMT2ASMN1; SMN2
SCHEMBL4422023 0.77 MAPT (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL4416119 0.77 SMN1; SMN2 (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL4413950 0.76 HTR7 (0.61) HTR1AHTR7MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-12-31 US claimed
US-8492384-B2 Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-07-23 US disclosed
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1B, CACNA1C, ORAI1 HTR1A 1240/4885HTR7 816/4885MEN1 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.